Literature DB >> 20871783

Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns.

A Rose Brannon1, Anupama Reddy, Michael Seiler, Alexandra Arreola, Dominic T Moore, Raj S Pruthi, Eric M Wallen, Matthew E Nielsen, Huiqing Liu, Katherine L Nathanson, Börje Ljungberg, Hongjuan Zhao, James D Brooks, Shridar Ganesan, Gyan Bhanot, W Kimryn Rathmell.   

Abstract

Clear cell renal cell carcinoma (ccRCC) is the predominant RCC subtype, but even within this classification, the natural history is heterogeneous and difficult to predict. A sophisticated understanding of the molecular features most discriminatory for the underlying tumor heterogeneity should be predicated on identifiable and biologically meaningful patterns of gene expression. Gene expression microarray data were analyzed using software that implements iterative unsupervised consensus clustering algorithms to identify the optimal molecular subclasses, without clinical or other classifying information. ConsensusCluster analysis identified two distinct subtypes of ccRCC within the training set, designated clear cell type A (ccA) and B (ccB). Based on the core tumors, or most well-defined arrays, in each subtype, logical analysis of data (LAD) defined a small, highly predictive gene set that could then be used to classify additional tumors individually. The subclasses were corroborated in a validation data set of 177 tumors and analyzed for clinical outcome. Based on individual tumor assignment, tumors designated ccA have markedly improved disease-specific survival compared to ccB (median survival of 8.6 vs 2.0 years, P = 0.002). Analyzed by both univariate and multivariate analysis, the classification schema was independently associated with survival. Using patterns of gene expression based on a defined gene set, ccRCC was classified into two robust subclasses based on inherent molecular features that ultimately correspond to marked differences in clinical outcome. This classification schema thus provides a molecular stratification applicable to individual tumors that has implications to influence treatment decisions, define biological mechanisms involved in ccRCC tumor progression, and direct future drug discovery.

Entities:  

Year:  2010        PMID: 20871783      PMCID: PMC2943630          DOI: 10.1177/1947601909359929

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  24 in total

1.  Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification.

Authors:  M Takahashi; D R Rhodes; K A Furge; H Kanayama ; S Kagawa; B B Haab; B T Teh
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

2.  A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma.

Authors:  Maximiliano Sorbellini; Michael W Kattan; Mark E Snyder; Victor Reuter; Robert Motzer; Manlio Goetzl; James McKiernan; Paul Russo
Journal:  J Urol       Date:  2005-01       Impact factor: 7.450

3.  Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system.

Authors:  John S Lam; Oleg Shvarts; John T Leppert; Allan J Pantuck; Robert A Figlin; Arie S Belldegrun
Journal:  J Urol       Date:  2005-08       Impact factor: 7.450

4.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

5.  High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates.

Authors:  Gabriela Alexe; Gul S Dalgin; Daniel Scanfeld; Pablo Tamayo; Jill P Mesirov; Charles DeLisi; Lyndsay Harris; Nicola Barnard; Maritza Martel; Arnold J Levine; Shridar Ganesan; Gyan Bhanot
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

6.  Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.

Authors:  Rosamonde E Banks; Prasanna Tirukonda; Claire Taylor; Nick Hornigold; Dewi Astuti; Dena Cohen; Eamonn R Maher; Anthea J Stanley; Patricia Harnden; Adrian Joyce; Margaret Knowles; Peter J Selby
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

7.  Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles.

Authors:  Kyle A Furge; Kerry A Lucas; Masayuki Takahashi; Jun Sugimura; Eric J Kort; Hiro-omi Kanayama; Susumu Kagawa; Philip Hoekstra; John Curry; Ximing J Yang; Bin T Teh
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

8.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.

Authors:  J G Herman; F Latif; Y Weng; M I Lerman; B Zbar; S Liu; D Samid; D S Duan; J R Gnarra; W M Linehan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

9.  Gene expression profiling predicts survival in conventional renal cell carcinoma.

Authors:  Hongjuan Zhao; Börje Ljungberg; Kjell Grankvist; Torgny Rasmuson; Robert Tibshirani; James D Brooks
Journal:  PLoS Med       Date:  2005-12-06       Impact factor: 11.069

10.  Logical Analysis of Data (LAD) model for the early diagnosis of acute ischemic stroke.

Authors:  Anupama Reddy; Honghui Wang; Hua Yu; Tiberius O Bonates; Vimla Gulabani; Joseph Azok; Gerard Hoehn; Peter L Hammer; Alison E Baird; King C Li
Journal:  BMC Med Inform Decis Mak       Date:  2008-07-10       Impact factor: 2.796

View more
  130 in total

Review 1.  Emerging molecular classification in renal cell carcinoma: implications for drug development.

Authors:  Kathryn E Hacker; W Kimryn Rathmell
Journal:  Target Oncol       Date:  2010-07-20       Impact factor: 4.493

2.  Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression.

Authors:  Samira A Brooks; Amir H Khandani; Julia R Fielding; Weili Lin; Tiffany Sills; Yueh Lee; Alexandra Arreola; Mathew I Milowsky; Eric M Wallen; Michael E Woods; Angie B Smith; Mathew E Nielsen; Joel S Parker; David S Lalush; W Kimryn Rathmell
Journal:  Clin Cancer Res       Date:  2016-01-19       Impact factor: 12.531

3.  Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade.

Authors:  Emanuela Taioli; William K Oh; Yixuan Gong; Li Wang; Haocheng Yu; Naomi Alpert; Mitchell D Cohen; Colette Prophete; Lori Horton; Maureen Sisco; Sung-Hyun Park; Hyun-Wook Lee; Judith Zelikoff; Lung-Chi Chen; Dana Hashim; Mayte Suarez-Farinas; Michael J Donovan; Stuart A Aaronson; Matthew Galsky; Jun Zhu
Journal:  Mol Cancer Res       Date:  2019-06-20       Impact factor: 5.852

4.  Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers.

Authors:  Jun Yao; Otavia L Caballero; W K Alfred Yung; John N Weinstein; Gregory J Riggins; Robert L Strausberg; Qi Zhao
Journal:  Cancer Immunol Res       Date:  2013-11-25       Impact factor: 11.151

5.  Integrative radiomics expression predicts molecular subtypes of primary clear cell renal cell carcinoma.

Authors:  Q Yin; S-C Hung; W K Rathmell; L Shen; L Wang; W Lin; J R Fielding; A H Khandani; M E Woods; M I Milowsky; S A Brooks; E M Wallen; D Shen
Journal:  Clin Radiol       Date:  2018-05-23       Impact factor: 2.350

6.  Deep sequencing reveals microRNAs predictive of antiangiogenic drug response.

Authors:  Jesús García-Donas; Benoit Beuselinck; Lucía Inglada-Pérez; Osvaldo Graña; Patrick Schöffski; Agnieszka Wozniak; Oliver Bechter; Maria Apellániz-Ruiz; Luis Javier Leandro-García; Emilio Esteban; Daniel E Castellano; Aranzazu González Del Alba; Miguel Angel Climent; Susana Hernando; José Angel Arranz; Manuel Morente; David G Pisano; Mercedes Robledo; Cristina Rodriguez-Antona
Journal:  JCI Insight       Date:  2016-07-07

7.  Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma.

Authors:  Huiqing Liu; Angela R Brannon; Anupama R Reddy; Gabriela Alexe; Michael W Seiler; Alexandra Arreola; Jay H Oza; Ming Yao; David Juan; Louis S Liou; Shridar Ganesan; Arnold J Levine; W K Rathmell; Gyan V Bhanot
Journal:  BMC Syst Biol       Date:  2010-04-27

8.  Robust multi-tissue gene panel for cancer detection.

Authors:  Joseph Irgon; C Chris Huang; Yi Zhang; Dmitri Talantov; Gyan Bhanot; Sándor Szalma
Journal:  BMC Cancer       Date:  2010-06-22       Impact factor: 4.430

Review 9.  Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact.

Authors:  Brandon J Manley; Abraham Ari Hakimi
Journal:  Curr Opin Urol       Date:  2016-09       Impact factor: 2.309

Review 10.  Adjuvant therapy for renal cell carcinoma: past, present, and future.

Authors:  Sumanta K Pal; Naomi B Haas
Journal:  Oncologist       Date:  2014-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.